<DOC>
	<DOCNO>NCT02781584</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability selonsertib ( GS-4997 ) , GS-0976 , GS-9674 adult nonalcoholic steatohepatitis ( NASH ) .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Selonsertib , GS-0976 , GS-9674 Adults With Nonalcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Males females 1875 year age ; inclusive base date screen visit Willing able provide inform consent prior study specific procedure perform Meets follow condition : Clinical diagnosis nonalcoholic fatty liver disease , screen FibroTest® &lt; 0.75 , unless historical liver biopsy within 12 month screen reveal cirrhosis , screen magnetic resonance image proton density fat fraction ( MRIPDFF ) ≥ 10 % steatosis , screen magnetic resonance elastography ( MRE ) liver stiffness ≥ 2.88 kPa OR A historical liver biopsy within 12 month screen consistent NASH ( define presence steatosis , inflammation , balloon ) stage 23 fibrosis accord NASH Clinical Research Network ( CRN ) classification ( equivalent ) document weight loss &gt; 5 % date liver biopsy screen Key Pregnant lactating females Other cause liver disease include autoimmune , viral , alcoholic liver disease Cirrhosis liver Any history decompensated liver disease , include ascites , hepatic encephalopathy variceal bleed History liver transplantation Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>